Membrane type-1 matrix metalloproteinase (MT1-MMP) correlates with the expression and activation of matrix metalloproteinase-2 (MMP-2) in inflammatory breast cancer

International Journal of Clinical and Experimental Medicine

Volumn 4, Issue 4, 2011, Pages 265-275

  Al Raawi, Diaa ^a   Abu El Zahab, Helal ^b   El Shinawi, Mohamed ^c   Mohamed, Mona Mostafa ^b  

^a SANA A UNIVERSITY   (Yemen)

^b CAIRO UNIVERSITY   (Egypt)

^c AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Inflammatory breast cancer; Matrix metalloproteinases; MMP 2; MMP 9; MT1 MMP

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE 14;

ADULT; AGED; ARTICLE; BRAIN TISSUE; CANCER TISSUE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BREAST CANCER; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; ZYMOGRAPHY;

EID: 82955168423     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Nouh MA, Mohamed MM, El-Shinawi M, Shaalan MA, Cavallo-Medved D, Khaled HM and Sloane BF. Cathepsin B: a potential prognostic marker for inflammatory breast cancer. J Transl Med 2011; 9: 1.
2. Hance KW, Anderson WF, Devesa SS, Young HA and Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 2005; 97: 966-975.
3. Giordano SH, Hortobagyi GN. Inflammatory breast cancer: clinical progress and the main problems that must be addressed. Breast Cancer Res 2003; 5: 284-288.
4. Van Laere SJ, Van den Eynden GG, Van der Auwera I, Vandenberghe M, van Dam P, Van Marck EA, van Golen KL, Vermeulen PB and Dirix LY. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res Treat 2006; 95: 243-255.
5. Lee M, Fridman R and Mobashery S. Extracellular proteases as targets for treatment of cancer metastases. Chem Soc Rev 2004; 33: 401-409.
6. Radisky ES, Radisky DC. Matrix metalloproteinase- induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia 2010; 15: 201-212.
7. Roy R, Yang J and Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009; 27: 5287-5297.
8. Coussens LM, Fingleton B and Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-2392.
9. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006; 25: 9-34.
10. Gonzalez LO, Junquera S, del Casar JM, Gonzalez L, Marin L, Gonzalez-Reyes S, Andicoechea A, Gonzalez-Fernandez R, Gonzalez JM, Perez-Fernandez R and Vizoso FJ. Immunohistochemical study of matrix metalloproteinases and their inhibitors in pure and mixed invasive and in situ ductal carcinomas of the breast. Hum Pathol 2010; 41: 980-989.
11. Hu J, Van den Steen PE, Sang QX and Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007; 6: 480-498.
12. Cao J, Sato H, Takino T and Seiki M. The Cterminal region of membrane type matrix metalloproteinase is a functional transmembrane domain required for pro-gelatinase A activation. J Biol Chem 1995; 270: 801-805.
13. Hotary KB, Allen ED, Brooks PC, Datta NS, Long MW and Weiss SJ. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003; 114: 33-45.
14. Sabeh F, Ota I, Holmbeck K, Birkedal-Hansen H, Soloway P, Balbin M, Lopez-Otin C, Shapiro S, Inada M, Krane S, Allen E, Chung D and Weiss SJ. Tumor cell traffic through the ex tracellular matrix is controlled by the membrane- anchored collagenase MT1-MMP. J Cell Biol 2004; 167: 769-781.
15. Barbolina MV, Stack MS. Membrane type 1- matrix metalloproteinase: substrate diversity in pericellular proteolysis. Semin Cell Dev Biol 2008; 19: 24-33.
16. Seiki M. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett 2003; 194: 1-11.
17. Yana I, Weiss SJ. Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases. Mol Biol Cell 2000; 11: 2387-2401.
18. Lee H, Sodek KL, Hwang Q, Brown TJ, Ringuette M and Sodek J. Phagocytosis of collagen by fibroblasts and invasive cancer cells is mediated by MT1-MMP. Biochem Soc Trans 2007; 35: 704-706.
19. Duffy MJ, Maguire TM, Hill A, McDermott E and O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000; 2: 252-257.
20. Hofmann UB, Westphal JR, Zendman AJ, Becker JC, Ruiter DJ and van Muijen GN. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol 2000; 191: 245-256.
21. Dasgupta S, Bhattacharya Chatterjee M, O'Malley BW Jr and Chatterjee SK. Tumor metastasis in an orthotopic murine model of head and neck cancer: possible role of TGFbeta 1 secreted by the tumor cells. J Cell Biochem 2006; 97: 1036-1051.
22. Wilson SR, Gallagher S, Warpeha K and Hawthorne SJ. Amplification of MMP-2 and MMP-9 production by prostate cancer cell lines via activation of protease-activated receptors. Prostate 2004; 60: 168-174.
23. Figueira RC, Gomes LR, Neto JS, Silva FC, Silva ID and Sogayar MC. Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer 2009; 9: 20.
24. Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mason MD and Mansel RE. Expression of membrane type-1 matrix metalloproteinase, MT1-MMP in human breast cancer and its impact on invasiveness of breast cancer cells. Int J Mol Med 2006; 17: 583-590.
25. Kohrmann A, Kammerer U, Kapp M, Dietl J and Anacker J. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer 2009; 9: 188.
26. Gonzalez LO, Pidal I, Junquera S, Corte MD, Vazquez J, Rodriguez JC, Lamelas ML, Merino AM, Garcia-Muniz JL and Vizoso FJ. Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis- relapse. Br J Cancer 2007; 97: 957-963.
27. Mohamed MM, Cavallo-Medved D, Rudy D, Anbalagan A, Moin K and Sloane BF. Interleukin-6 increases expression and secretion of cathepsin B by breast tumor-associated monocytes. Cell Physiol Biochem 2010; 25: 315-324.
28. Mylona E, Nomikos A, Magkou C, Kamberou M, Papassideri I, Keramopoulos A and Nakopoulou L. The clinicopathological and prognostic significance of membrane type 1 matrix metalloproteinase (MT1-MMP) and MMP-9 according to their localization in invasive breast carcinoma. Histopathology 2007; 50: 338-347.
29. Young TN, Rodriguez GC, Rinehart AR, Bast RC Jr, Pizzo SV and Stack MS. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecol Oncol 1996; 62: 89-99.
30. Sun XM, Dong WG, Yu BP, Luo HS and Yu JP. Detection of type IV collagenase activity in malignant ascites. World J Gastroenterol 2003; 9: 2592-2595.
31. Rozanov DV, Savinov AY, Williams R, Liu K, Golubkov VS, Krajewski S and Strongin AY. Molecular signature of MT1-MMP: transactivation of the downstream universal gene network in cancer. Cancer Res 2008; 68: 4086-4096.
32. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA and Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995; 270: 5331-5338.
33. Toth M, Chvyrkova I, Bernardo MM, Hernandez-Barrantes S and Fridman R. Pro-MMP-9 activation by the MT1-MMP/MMP-2 axis and MMP-3: role of TIMP-2 and plasma membranes. Biochem Biophys Res Commun 2003; 308: 386-395.
34. Ueno H, Nakamura H, Inoue M, Imai K, Noguchi M, Sato H, Seiki M and Okada Y. Expression and tissue localization of membranetypes 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res 1997; 57: 2055-2060.
35. Gonzalez LO, Gonzalez-Reyes S, Marin L, Gonzalez L, Gonzalez JM, Lamelas ML, Merino AM, Rodriguez E, Pidal I, del Casar JM, Andicoechea A and Vizoso F. Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumour stromal mononuclear inflammatory cells and those at the invasive front of breast carcinomas. Histopathology 2010; 57: 862-876.
36. Liu SC, Yang SF, Yeh KT, Yeh CM, Chiou HL, Lee CY, Chou MC and Hsieh YS. Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer. Clin Chim Acta 2006; 371: 92-96.
37. Ishigaki S, Toi M, Ueno T, Matsumoto H, Muta M, Koike M and Seiki M. Significance of membrane type 1 matrix metalloproteinase expression in breast cancer. Jpn J Cancer Res 1999; 90: 516-522.
38. Tetu B, Brisson J, Wang CS, Lapointe H, Beaudry G, Blanchette C and Trudel D. The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res 2006; 8: R28.
39. Kim HJ, Park CI, Park BW, Lee HD and Jung WH. Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. Yonsei Med J 2006; 47: 333-342.
40. Shah FD, Shukla SN, Shah PM, Shukla HK and Patel PS. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer. Indian J Cancer 2009; 46: 194-202.
41. Garcia MF, Gonzalez Reyes S, Gonzalez LO, Junquera S, Berdize N, Del Casar JM, Medina M and Vizoso FJ. Comparative study of the expression of metalloproteases and their inhibitors in different localizations within primary tumours and in metastatic lymph nodes of breast cancer. Int J Exp Pathol 2010; 91: 324-334.
42. Duffy MJ, McGowan PM and Gallagher WM. Cancer invasion and metastasis: changing views. J Pathol 2008; 214: 283-293.
43. Zheng SQ, Huang RQ and Zhang YJ. Role of matrix metalloproteinase (MMP)-2 and -9 and vascular endothelial growth factor C in lymph node metastasis of breast cancer. Zhonghua Bing Li Xue Za Zhi 2010; 39: 240-244.
44. Strongin AY. Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy. Biochim Biophys Acta 2010; 1803: 133-141.
45. Patel S, Sumitra G, Koner BC and Saxena A. Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression. Clin Biochem 2011; 44: 869-872.
46. Stankovic S, Konjevic G, Gopcevic K, Jovic V, Inic M and Jurisic V. Activity of MMP-2 and MMP-9 in sera of breast cancer patients. Pathol Res Pract 2010; 206: 241-247.
47. Kleer CG, van Golen KL and Merajver SD. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2000; 2: 423-429.
48. Kousidou OC, Roussidis AE, Theocharis AD and Karamanos NK. Expression of MMPs and TIMPs genes in human breast cancer epithelial cells depends on cell culture conditions and is associated with their invasive potential. Anticancer Res 2004; 24: 4025-4030.
49. Banerji A, Chakraborti J, Mitra A and Chatterjee A. Cell membrane-associated MT1-MMPdependent activation of pro-MMP-2 in A375 melanoma cells. J Environ Pathol Toxicol Oncol 2005; 24: 3-17.
50. Di Nezza LA, Misajon A, Zhang J, Jobling T, Quinn MA, Ostor AG, Nie G, Lopata A and Salamonsen LA. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer 2002; 94: 1466-1475.
51. Itoh Y, Takamura A, Ito N, Maru Y, Sato H, Suenaga N, Aoki T and Seiki M. Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J 2001; 20: 4782-4793.
52. Kim IY, Jeong SJ, Kim ES, Kim SH and Moon A. Type I collagen-induced pro-MMP-2 activation is differentially regulated by H-Ras and N-Ras in human breast epithelial cells. J Biochem Mol Biol 2007; 40: 825-831.
53. Sounni NE, Noel A. Membrane type-matrix metalloproteinases and tumor progression. Biochimie 2005; 87: 329-342.
54. Fridman R, Toth M, Pena D and Mobashery S. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 1995; 55: 2548-2555.
55. Ogata Y, Enghild JJ and Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 1992; 267: 3581-3584.
56. Ramos DeSimone N, Hahn Dantona E, Sipley J, Nagase H, French DL and Quigley JP. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 1999; 274: 13066-13076.
57. Sang QX, Birkedal Hansen H and Van Wart HE. Proteolytic and non-proteolytic activation of human neutrophil progelatinase B. Biochim Biophys Acta 1995; 1251: 99-108.
58. Knauper V, Smith B, Lopez Otin C and Murphy G. Activation of progelatinase B (proMMP-9) by active collagenase-3 (MMP-13). Eur J Biochem 1997; 248: 369-373.
59. Uria JA, Lopez Otin C. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. Cancer Res 2000; 60: 4745-4751.